Advaxis to Participate in Five Upcoming Industry Conferences

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis,
Inc. (NASDAQ: ADXS), a late-stage biotechnology
company focused on the discovery, development and commercialization of
immunotherapy products, announces participation in five upcoming
industry conferences:

BioNJ 9^th Annual BioPartnering Conference

• Date and Time: Wednesday, May 8, 2019 at 2:00pm ET
• Venue: The Palace at Somerset Park – Gatsby Suite, Somerset, New Jersey
• Presenter: Molly Henderson, Executive Vice President and Chief
  Financial Officer
• Presentation: Corporate overview

Frontiers in Cancer Immunotherapy

• Date: Tuesday, May 14, 2019
• Venue: The New York Academy of Sciences, New York, New York
• Presenter: Robert Petit, Ph.D., Chief Scientific Officer
• Two Poster Presentations: Safety and Immunogenicity of a
  Personalized Neoantigen-Listeria Vaccine in Cancer Patients; and Effects
  of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen
  Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients
  (Results from KEYNOTE-046)

Immuno-Oncology Xchange

• Date and Time: Wednesday, May 15, 2019 at 12:30pm ET
• Venue: Seaport World Trade Center, Boston, Massachusetts
• Presenter: Andres A. Gutierrez, M.D. Ph.D., Chief Medical Officer
• Presentation: Challenges of First-in-Human Phase I Dose-Escalating
  Trials in Patients with Advanced Cancers

BIO International Convention

• Date: June 3-6, 2019
• Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania
• Management holding partnering meetings: Ken Berlin, President and
  Chief Executive Officer, and Molly Henderson, Executive Vice President
  and Chief Financial Officer

IO Combinations 360°

• Date and Time: June 20-21, 2019 at 12:00pm ET
• Venue: Wyndham Historic District Hotel, Philadelphia, Pennsylvania
• Presenter: J. Randolph Hecht M.D., Professor of Clinical Medicine,
  David Geffen School of Medicine at UCLA and Director of the UCLA
  Gastrointestinal Oncology Program
• Presentation: A Phase 1 Dose-Escalation Study of ADXS-NEO
  Expressing Personalized Tumor Antigens in Subjects with Advanced Solid
  Tumors: Updated Results

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the
discovery, development and commercialization of proprietary Lm-based
antigen delivery products. These immunotherapies are based on a platform
technology that utilizes live attenuated Listeria monocytogenes (Lm)
bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in immunotherapy as
they integrate multiple functions into a single immunotherapy and are
designed to access and direct antigen presenting cells to stimulate
anti-tumor T cell immunity, activate the immune system with the
equivalent of multiple adjuvants, and simultaneously reduce tumor
protection in the tumor microenvironment to enable T cells to eliminate
tumors. Advaxis has four programs in various stages of clinical
development: ADXS-HPV for cervical cancer; ADXS-NEO, a personalized
neoantigen-directed therapy for multiple cancers; ADXS-503 for non-small
cell lung cancer, from its ADXS-HOT off-the-shelf neoantigen-directed
program; and ADXS-PSA for prostate cancer.

To learn more about Advaxis, visit www.advaxis.com
and connect on Twitter, LinkedIn, Facebook and YouTube.

Advaxis Forward-Looking Statement

Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The factors that could cause
our actual results to differ materially include: the success and timing
of our clinical trials, including subject accrual; our ability to avoid
any clinical holds and to resolve FDA’s partial clinical hold; our
ability to obtain and maintain regulatory approval and/or reimbursement
of our product candidates for marketing; our ability to obtain the
appropriate labeling of our products under any regulatory approval; our
plans to develop and commercialize our products; the successful
development and implementation of our sales and marketing campaigns; the
size and growth of the potential markets for our product candidates and
our ability to serve those markets; our ability to successfully compete
in the potential markets for our product candidates, if commercialized;
regulatory developments in the United States and other countries; the
rate and degree of market acceptance of any of our product candidates;
new products, product candidates or new uses for existing products or
technologies introduced or announced by our competitors and the timing
of these introductions or announcements; market conditions in the
pharmaceutical and biotechnology sectors; our available cash; the
accuracy of our estimates regarding expenses, future revenues, capital
requirements and needs for additional financing; our ability to obtain
additional funding; our ability to obtain and maintain intellectual
property protection for our product candidates; the success and timing
of our preclinical studies including IND-enabling studies; the timing of
our IND submissions; our ability to get FDA approval for study
amendments; the timing of data read-outs; the ability of our product
candidates to successfully perform in clinical trials; our ability to
initiate, enroll, and execute pilots and clinical trials; our ability to
maintain collaborations; our ability to manufacture and the performance
of third-party manufacturers; the performance of our clinical research
organizations, clinical trial sponsors and clinical trial investigators;
our ability to successfully implement our strategy; and, other risk
factors identified from time to time in our reports filed with the SEC.
Any forward-looking statements set forth in this press release speak
only as of the date of this press release. We do not intend to update
any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.

Contacts

Investors:
LHA Investor Relations
Yvonne Briggs, (310) 691-7100
[email protected]